Idarucizumab

Why this drug is interesting

Almost every other reversal agent on this site makes you do arithmetic. Prothrombin complex concentrate is dosed on weight and INR. Andexanet alfa has a high and a low regimen chosen by dose and timing. Phytomenadione is titrated to INR and to whether the patient is bleeding. Idarucizumab has one dose: 5 g, both vials, everyone.

That simplicity is not a marketing convenience — it falls out of the mechanism. Idarucizumab is a stoichiometric binder given in vast molar excess of any plausible dabigatran burden. There is nothing to titrate because the drug is not modulating a pathway; it is mopping up a molecule.

Pharmacology

Mechanism

Idarucizumab is a humanised monoclonal antibody fragment (Fab) raised against dabigatran. It binds dabigatran and its acylglucuronide metabolites with an affinity approximately 300-fold greater than dabigatran's affinity for thrombin.¹ The complex has a rapid on-rate and an extremely slow off-rate, so once formed it does not meaningfully dissociate.

Because it is a Fab and not a whole antibody, it has no Fc region, no complement activation and no thrombin-like activity of its own. The SmPC states that idarucizumab alone shows no procoagulant effect on endogenous thrombin potential — it is not a haemostatic agent, it is a sponge.¹

Pharmacokinetics

Onset

Immediate — dilute thrombin time and ecarin clotting time normalise by the end of the infusion¹

Distribution

Largely confined to plasma, matching dabigatran's distribution

Elimination

Renal, with proteolytic catabolism typical of a Fab fragment

Renal impairment

No dose adjustment. Renal impairment did not affect the reversal effect¹

Hepatic impairment

No dose adjustment¹

Elderly

No dose adjustment in patients ≥65¹

Dosing

The dose

5 g idarucizumab — two vials of 2.5 g in 50 mL. Given intravenously as two consecutive infusions over 5 to 10 minutes each, or as a bolus injection.¹ Restricted to hospital use.

There is no weight band, no renal correction, no age adjustment and no loading-then-infusion structure. The whole posology section fits in a sentence.

The second dose

In a subset of patients, unbound dabigatran concentrations and prolonged clotting times recur up to 24 hours after idarucizumab.¹ This is redistribution of dabigatran out of the extravascular compartment after the intravascular drug has been bound, and it is the single most important thing to know beyond the dose.

A second 5 g dose may be considered when:

• Clinically relevant bleeding recurs together with prolonged clotting times, or
• Potential re-bleeding would be life-threatening and clotting times are prolonged, or
• A second emergency procedure is required and clotting times are prolonged.

Paediatrics

Safety and efficacy under 18 years are not established. The entire paediatric dataset in the SmPC is one patient aged 16–17, treated with 5 g, in whom reversal was rapid and complete and the pharmacokinetics matched adults.¹ That is a case report inside a label, not a licence.

Restarting anticoagulation

• Dabigatran can be restarted 24 hours after idarucizumab if the patient is clinically stable and haemostasis is adequate.¹ At 24 hours, re-administered dabigatran produces the expected anticoagulant effect — idarucizumab does not block it.
• Other antithrombotic therapy (e.g. low-molecular-weight heparin) can be started at any time if stable, because idarucizumab does not bind it.¹
• Absence of antithrombotic therapy exposes the patient to the thrombotic risk of whatever they were anticoagulated for in the first place.

What it does not reverse

The SmPC lists, from preclinical work, the agents idarucizumab shows no interaction with — which is the same list of things it will not reverse:¹

• Factor Xa inhibitors — apixaban, rivaroxaban, edoxaban. For these, see andexanet alfa and prothrombin complex concentrate.
• Low-molecular-weight and unfractionated heparin — see protamine sulfate.
• Vitamin K antagonists — see phytomenadione and PCC.
• Direct thrombin inhibitors other than dabigatran — argatroban, bivalirudin.

It also does not interact with volume expanders, PCCs, activated PCCs or recombinant factor VIIa — so standard haemostatic measures can run alongside it.¹

Evidence

RE-VERSE AD

The clinical dataset is one prospective, open-label, non-randomised, uncontrolled study.¹² There is no control arm anywhere in the idarucizumab programme, which is worth stating plainly before quoting any of its numbers.

RE-VERSE AD enrolled 503 patients: 301 with serious bleeding (group A) and 202 requiring an urgent procedure (group B). Median age 78, median creatinine clearance 52.6 mL/min.¹

The 20% mortality and the 34 thrombotic events are attributed by the label to the index event and to underlying comorbidity. In an 78-year-old population anticoagulated for a reason, with no control arm, that attribution cannot be tested. Do not present idarucizumab as having a demonstrated survival benefit; it has a demonstrated pharmacodynamic effect and a plausible clinical one.

Preclinical

In a pig blunt liver injury model at roughly 10× human plasma dabigatran levels, idarucizumab reversed life-threatening bleeding within 15 minutes and all animals survived at 2.5 g and 5 g equivalents; untreated anticoagulated mortality was 100%.¹ This is where the dramatic survival numbers come from — they are pigs.

Safety

Adverse effects

Section 4.8 of the SmPC, across 503 patients, 224 volunteers and a 359-patient surveillance programme, reads in full: "No adverse reactions have been identified."¹ That is unusual for any drug and reflects both a genuinely clean molecule and an uncontrolled dataset in very sick people where attribution is near-impossible.

The three real cautions

Hereditary fructose intolerance

The 5 g dose contains 4 g sorbitol. Parenteral sorbitol in HFI has caused hypoglycaemia, hypophosphataemia, metabolic acidosis, acute liver failure and death. If given, intensified care is required during exposure and for 24 hours afterwards.¹

Hypersensitivity

Weigh known hypersensitivity to idarucizumab or excipients against the benefit; stop immediately if an anaphylactic reaction occurs. Mild potential hypersensitivity symptoms (pyrexia, bronchospasm, hyperventilation, rash, pruritus) were reported in RE-VERSE AD without an established causal link.¹

Thromboembolism

Reversal returns the patient to their untreated thrombotic risk. Resume anticoagulation as soon as it is medically appropriate.¹

Practical use in the ED

1. Confirm the drug is dabigatran. Not "a blood thinner", not "a DOAC". If it is apixaban or rivaroxaban, this is the wrong vial.
2. Send coagulation studies before giving it — aPTT, and dTT or ECT where available. A normal thrombin time essentially excludes clinically relevant dabigatran and should make you pause.
3. Give 5 g — both vials. Two infusions of 5–10 minutes each, or bolus. No calculation.
4. Do not stop resuscitating. Idarucizumab reverses a drug; it does not replace transfusion, tranexamic acid where indicated, source control or neurosurgical referral.
5. Plan for 24 hours. Recurrent bleeding with re-prolonged clotting times within that window is the trigger for a second 5 g dose, not a treatment failure.
6. Book the anticoagulation restart conversation before the patient leaves your department. Dabigatran at 24 hours if stable; anything else can start sooner.

Critical appraisal

Idarucizumab is the most convincing of the DOAC reversal agents on mechanism and the least convincing on outcome evidence — a combination it shares with almost everything in this class. There is no randomised trial, and there will not be one. The molecule does exactly what it is designed to do, immediately and completely, and the remaining uncertainty is entirely about whether normalising a coagulation assay in an elderly bleeding patient changes what happens to them.

Set against andexanet alfa, idarucizumab is the better drug on every practical axis: no dose selection, no timing rule, no contraindications, no heparin unresponsiveness, and no NICE funding restriction to a single bleeding site. That comparison is not a triumph of pharmacology so much as an accident of target — a small molecule with a single binding site is simply an easier thing to sequester than a class of factor Xa inhibitors.

References

1. 1
   Praxbind 2.5 g/50 mL solution for injection/infusion — Summary of Product Characteristics. electronic Medicines Compendium, product 5073. Sections 4.1–4.9, 5.1, 5.2. Source of the 5 g fixed dose, the second-dose criteria, the 24-hour rebound, the sorbitol content, the RE-VERSE AD figures and the empty adverse-reaction section. Verified 31 Aug 2026.
2. 2
   Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal — full cohort analysis. N Engl J Med 2017;377:431–441. PubMed 28693366. The published RE-VERSE AD cohort; open-label, uncontrolled, no comparator arm.